Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07595549 · ClinicalTrials.gov registry record · Phase 3
A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
A Phase 3 study, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 954
- Enrollment target
NCT07595549: Recruiting Phase 3 study, sponsored by Pfizer.
NCT07595549 is a Phase 3 study that is actively recruiting participants, run by Pfizer. The registered enrollment target is 954 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (24% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07595549, a Phase 3 study, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 954 participants
- Enrollment target
Study Summary
The purpose of this clinical study is to learn about the effects and safety of berobenatide (PF-08653944). This may help people with overweight or obesity lose weight. People in this study may also have type 2 diabetes. About 950 adults will be in this study. Berobenatide will be compared to a placebo. A placebo does not have any medicine in it but looks just like the medicine being studied. Berobenatide or placebo is given by a shot under the skin in the belly area. The objective of the study is to compare the experiences of people receiving berobenatide to those of the people who do not to assess if the study medicine is effective and safe. People will take part in this study for about 20 months. During this time, they will have about 15 study visits at the site. They will also have 2 study visits over the phone.
Interventions
- OTHER Placebo
- DRUG PF-08653944
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 954 participants |
| Start Date | 2026-06-10 |
| Est. Completion | 2028-06-21 |
| Phase | Phase 3 |
What NCT07595549 shows while recruiting
NCT07595549 is an interventional study that assigns participants to a tested intervention. The registered 954 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (24% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07595549 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07595549 about?
NCT07595549 is a clinical study titled "A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity". The purpose of this clinical study is to learn about the effects and safety of berobenatide (PF-08653944). This may help people with overweight or obesity lose weight. People in this study may also have type 2 diabetes. About 950 adults will be in this study. Berobenatide will be compared to a plac...
What is the current status of trial NCT07595549?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 954 participants. The study started on 2026-06-10. Estimated completion is 2028-06-21.
What interventions are being tested in trial NCT07595549?
The interventions under investigation include: Placebo (OTHER), PF-08653944 (DRUG).
Who is sponsoring clinical trial NCT07595549?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07595549's enrollment target sits among peer trials
954 333rd of 2000 higher than 1,668 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06225596 · 956 participants · Phase 2
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
- NCT04375033 · 952 participants · Phase 4
A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder
- NCT06259669 · 958 participants
Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population
- NCT03784924 · 950 participants
EDRN Prostate MRI Biomarker Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI